Patents by Inventor Pradeep Shivakumar
Pradeep Shivakumar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230158012Abstract: The present invention relates to oral liquid formulations comprising lenvatinib or pharmaceutically acceptable salts or solvates thereof with improved stability and palatability. Further the present invention relates to an oral pharmaceutical suspension comprising lenvatinib or pharmaceutically acceptable salt, solvate or hydrate thereof and pharmaceutically acceptable excipients, wherein pharmaceutically acceptable excipients are selected from suspending agents, wetting agents, stabilizing agents, vehicle, organic co-solvents, sweeteners, flavoring agents, preservatives, antioxidants and buffering agents.Type: ApplicationFiled: May 13, 2021Publication date: May 25, 2023Applicant: SHILPA MEDICARE LTDInventors: NIJAGUNI REVANSIDDAYYA RUDRASWAMY MATH, PRADEEP SHIVAKUMAR
-
Publication number: 20230016551Abstract: The present invention provides the method and/or compositions for administering a therapeutically effective amount of ursodeoxycholic acid (UDCA) intravenously for the treatment and/or the prevention of liver diseases, preferably chronic liver diseases. The present invention also relates to methods of intravenous administration of UDCA in a dose of about 15 mg/kg to about 200 mg/ kg at a dosage interval of once every 12 hours to once every 72 hours.Type: ApplicationFiled: January 21, 2021Publication date: January 19, 2023Applicant: SHILPA MEDICARE LTDInventors: PALMIERI BENIAMINO, PRADEEP SHIVAKUMAR, KRISHNAMURTHY TOPPALADODDI
-
Publication number: 20220378803Abstract: The present invention is directed to an injectable pharmaceutical composition comprising (a) ursodeoxycholic acid and (b) sulfobutylether-?-cyclodextrin. Such compositions exhibit unexpected solubility and stability of ursodeoxycholic acid permitting therapeutic dosages of the ursodeoxycholic acid to be administered without the use of high amounts of strong bases that are present in an amount stoichiometrically equivalent to the ursodeoxycholic acid. The present invention is directed to an injectable pharmaceutical composition comprising (a) ursodeoxycholic acid and (b) sulfobutylether-?-cyclodextrin. Such compositions exhibit unexpected solubility and stability of ursodeoxycholic acid permitting therapeutic dosages of the ursodeoxycholic acid to be administered without the use of high amounts of strong bases that are present in an amount stoichiometrically equivalent to the ursodeoxycholic acid.Type: ApplicationFiled: November 19, 2020Publication date: December 1, 2022Applicant: SHILPA MEDICARE LTDInventors: PRADEEP SHIVAKUMAR, PURUSHOTHAMA NARASIYAPPA, KIRAN KUMAR CHERUKURI
-
Publication number: 20220354828Abstract: The present invention relates to a controlled release injectable ondansetron formulation comprising ondansetron or pharmaceutically acceptable salt, derivative or metabolite thereof which releases ondansetron over a period of at least 2 days period from the date of administration and the process for preparation thereof.Type: ApplicationFiled: September 30, 2020Publication date: November 10, 2022Applicant: SHILPA MEDICARE LTDInventors: PURUSHOTHAMA NARASIYAPPA, KIRAN KUMAR CHERUKURI, VIVEK VIJAYA KUMAR JOSHI, PRADEEP SHIVAKUMAR, SREENIVASA REDDY
-
Publication number: 20220288009Abstract: The present invention relates to the stable liquid pharmaceutical composition comprising (a) cabazitaxel or a pharmaceutically acceptable salt or solvate thereof, (b) one or more solubilizers selected from the group consisting of soya phosphatidyl choline, polyethylene glycol and glycocholic acid, (c) a solvent and (d) a co-solvent, wherein the pharmaceutical composition is substantially free of (i) polysorbates and (ii) stabilizers selected from the group consisting of preservatives, antioxidants and chelating agents and the process for preparation thereof, and the methods of using the stable liquid pharmaceutical composition of cabazitaxel for the treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel containing treatment regimen.Type: ApplicationFiled: September 3, 2020Publication date: September 15, 2022Applicant: SHILPA MEDICARE LTDInventors: KIRAN KRISHNAPPA JADHAV, PRASHANTH SHANKAR, PRADEEP SHIVAKUMAR, SREENIVASA REDDY
-
Publication number: 20210401765Abstract: The present invention relates to topical spray compositions comprising chitosan and the process for preparation thereof. The topical spray compositions comprising chitosan are used for the treating burn wounds, wounds resulting from chemical burns, wounds from physical trauma, neuropathic ulcers, pressure sores, diabetic ulcers. Further the spray compositions composition is used for treating gynaecological diseases, urogenital infections (vaginal bacteriosis, urinary tract infection and vaginitis) with good effect, safe, natural, and good biocompatibility by restoring and/or maintaining the pH of vagina. More specifically the present invention relates to topical spray compositions comprising chitosan and carbonic acid and the process for preparation thereof.Type: ApplicationFiled: October 18, 2019Publication date: December 30, 2021Applicant: SHILPA MEDICARE LTDInventors: PURUSHOTHAMA NARASIYAPPA, KIRAN KUMAR CHERUKURI, VIVEK VIJAYA KUMAR JOSHI, PRADEEP SHIVAKUMAR, SREENIVASA REDDY
-
Publication number: 20210137958Abstract: The present invention relates to stable liquid pharmaceutical composition of decitabine comprising decitabine and at least one pharmaceutically acceptable excipient, wherein moisture content of the liquid composition is less than about 2.0% by weight. The invention further relates to stable liquid composition of decitabine wherein the total impurities of the composition is less than about 2.0% by weight when stored at 25° C./60% RH for at least 6 months. The invention further relates to method of using such stable liquid compositions of decitabine for parenteral administration either as ready-to-use or ready-to-dilute for treating various cancer disorders.Type: ApplicationFiled: May 23, 2019Publication date: May 13, 2021Applicant: SHILPA MEDICARE LTDInventors: PRADEEP SHIVAKUMAR, PURUSHOTHAMA NARASIYAPPA, KIRAN KUMAR CHERUKURI, SREENIVASA REDDY
-
Publication number: 20210060017Abstract: The present invention relates to a topical ophthalmic composition formulated for application to the eye, said composition comprising a therapeutically effective amount of methotrexate for the treatment of anterior uveitis. Preferably anterior uveitis is auto immune mediated and non-infectious. Further the present invention relates to a method of treating anterior uveitis of the mammalian eye, said method comprising administering to the mammal in eye about 5 ?g to about 200 ?g of methotrexate.Type: ApplicationFiled: February 22, 2019Publication date: March 4, 2021Applicant: SHILPA MEDICARE LTDInventors: ANDANAYYA SARGANACHARI, SANDEEP SUKUMAR, SREENIVASA REDDY, PRADEEP SHIVAKUMAR, THIPPESWAMY AHM
-
Patent number: 9789113Abstract: The present application provides pharmaceutical compositions derived from pemetrexed dipotassium Nonahydrate and its process thereof. The present application also provides a method of treating cancer by administering intravenously the reconstituted lyophilized compositions into a patient in need thereof.Type: GrantFiled: June 23, 2015Date of Patent: October 17, 2017Assignee: SHILPA MEDICARE LIMITEDInventors: Pradeep Shivakumar, Akshay Kant Chaturvedi
-
Patent number: 9765108Abstract: The present invention relates to polymorphic forms of 5-Azacytidine and the process for preparation thereof. The present invention further relates to Crystalline 5-azacytidine 5 designated as Form-SA-1 characterized by an X-ray powder diffraction pattern having at least four characteristic diffraction angle peaks at about 12.00, 12.60, 13.90, 15.15 and 31.40±0.20 2?°, which is useful as active pharmaceutical ingredient in pharmaceutical compositions for the treatment of myelodysplastic syndrome.Type: GrantFiled: November 8, 2013Date of Patent: September 19, 2017Assignee: SHILPA MEDICARE LIMITEDInventors: Pradeep Shivakumar, Nagaraju Dasari, Ravi Kishore, Rizwan Ahmed, Akshaykant Chaturvedi
-
Publication number: 20170100403Abstract: The present application provides pharmaceutical compositions derived from pemetrexed dipotassium Nonahydrate and its process thereof. The present application also provides a method of treating cancer by administering intravenously the reconstituted lyophilized compositions into a patient in need thereof.Type: ApplicationFiled: June 23, 2015Publication date: April 13, 2017Applicant: SHILPA MEDICARE LIMITEDInventors: PRADEEP SHIVAKUMAR, AKSHAY KANT CHATURVEDI
-
Publication number: 20160143850Abstract: The invention relates to a granulate composition comprising 90-99.95% w/w of Imatinib mesylate, 0.05-0.2% w/w of binder and 0-8% w/w of disintegrant, wherein the granulate composition is prepared using binder in isopropyl alcohol solvent. The invention also relates to pharmaceutical compositions comprising Imatinib mesylate, with high polymorphic stability and processes for preparation thereof. Said granulate composition comprising 90-99.95% w/w of Imatinib mesylate and their pharmaceutical compositions derived may be useful in the treatment of cancer.Type: ApplicationFiled: June 25, 2014Publication date: May 26, 2016Applicant: SHILPA MEDICARE LIMITEDInventors: PRADEEP SHIVAKUMAR, KRISHNAMURTHY TOPPALADODDI, SANJAY UMACHIGI, BADRINATH ALAMPALLI, AKSHAYKANT CHATURVEDI
-
Publication number: 20150284421Abstract: The present invention relates to lyophilized formulations comprising crystalline 5-azacytidine and process for preparing lyophilized formulations comprising crystalline 5-azacytidine.Type: ApplicationFiled: November 8, 2013Publication date: October 8, 2015Applicant: SHILPA MEDICARE LIMITEDInventors: Pradeep Shivakumar, Nagaraju Dasari, Ravi Kishore, Rizwan Ahmed, Akshaykant Chaturvedi